Decoding Drug Response With Structurized Gridding Map-Based Cell Representation.

Journal: IEEE journal of biomedical and health informatics
Published Date:

Abstract

A thorough understanding of cell-line drug response mechanisms is crucial for drug development, repurposing, and resistance reversal. While targeted anticancer therapies have shown promise, not all cancers have well-established biomarkers to stratify drug response. Single-gene associations only explain a small fraction of the observed drug sensitivity, so a more comprehensive method is needed. However, while deep learning models have shown promise in predicting drug response in cell lines, they still face significant challenges when it comes to their application in clinical applications. Therefore, this study proposed a new strategy called DD-Response for cell-line drug response prediction. First, a limitation of narrow modeling horizons was overcome to expand the model training domain by integrating multiple datasets through source-specific label binarization. Second, a modified representation based on a two-dimensional structurized gridding map (SGM) was developed for cell lines & drugs, avoiding feature correlation neglect and potential information loss. Third, a dual-branch, multi-channel convolutional neural network-based model for pairwise response prediction was constructed, enabling accurate outcomes and improved exploration of underlying mechanisms. As a result, the DD-Response demonstrated superior performance, captured cell-line characteristic variations, and provided insights into key factors impacting cell-line drug response. In addition, DD-Response exhibited scalability in predicting clinical patient responses to drug therapy. Overall, because of DD-response's excellent ability to predict drug response and capture key molecules behind them, DD-response is expected to greatly facilitate drug discovery, repurposing, resistance reversal, and therapeutic optimization.

Authors

  • Jiayi Yin
    Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
  • Hanyu Zhang
    Department of Environmental Science and Engineering, Beijing Technology and Business University, Beijing 100048, China.
  • Xiuna Sun
    College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Nanxin You
    Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
  • Minjie Mou
    College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Mingkun Lu
    College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
  • Ziqi Pan
    College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
  • Fengcheng Li
    College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
  • Honglin Li
    Innovation Center for AI and Drug Discovery, East China Normal University, China.
  • Su Zeng
    Laboratory of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
  • Feng Zhu
    Department of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, People's Republic of China.